Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

What's Hot in PD? Update on the Use of Mucuna Pruriens for the Treatment of Parkinson’s Disease

Mucuna pruriens variant utilis (MP) has long been used as an alternative to over-the-counter levodopaThe medication most commonly given to control the movement symptoms of Parkinson’s, usually with carbidopa. It is converted in the brain into dopamine.. MP is a leguminous plant that grows in both tropical and subtropical environments. Hidden in its seed is levodopa, which is the most important medication for a person with Parkinson’s disease. In this month’s What’s Hot we will review the studies supporting MP use and discuss future directions and global implications for this therapy.

In 2004, Katzenschlager performed a double blind study of MP. Though the study was small and included only eight Parkinson's disease subjects, it was a well-done, randomized, double-blind, crossover trial. The subjects were administered single doses of 50/200 mg Sinemet, and 15 and 30 grams of MP at several weekly intervals. The authors used the Unified Parkinson's Disease Rating Scale and tapping speed to assess changes. They also recorded dyskinesiaAbnormal, involuntary body movements that can appear as jerking, fidgeting, twisting and turning movements; frequently caused by dopaminergic medications to treat Parkinson’s. and adverse events. The MP group had a faster onset of effect (34.6 v 68.5 minutes; p = 0.021), which was also shown in blood studies of the pharmacodynamics. “On” time When medications are working and you experience good symptom control. was longer in the MP group, and there were no differences in adverse effects or in the development of dyskinesia. The Katzenschlager study used a processed pill form of MP (Katzenschlager, 2004).

This week, a paper by Cilia and colleagues describes another study of single-dose MP, but in their study the formulation was completely natural, not pharmacologically processed. The Cilia study used the powder taken directly from roasted MP seeds. Eighteen Parkinson’s disease patients were tested in 6 conditions, including a placebo condition. The Unified Parkinson’s Disease Rating Scale motor scores were recorded at 90 and 180 minutes. The authors  also measured the onset and duration of action. The UPDRS scores that showed motor improvement were similar in the MP and levodopa groups. Both preparations were better than the placebo condition. There were less dyskinesia and adverse events in the MP groups. The higher dose MP had a better "on" response and a longer duration of action (Cilia, 2017).

These studies support the idea that MP is a safe alternative to over-the-counter levodopa. There may be some benefits including a faster onset, longer life, and fewer adverse events, but the results of these studies should be interpreted with caution. There were very few patients in both studies, and the findings may not be representative of the wide spectrum of people with Parkinson’s disease. Additionally, the management of Parkinson’s disease is complicated and dynamic. Frequent changes and adjustments to medication usually underpin successful management. Using an over-the-counter pill form or a natural powder form could prove challenging to adjust and to manage even for the most experienced practitioner. If you are interested in MP, we recommend that it be managed by a neurologist with expertise in Parkinson’s disease. A larger and longer-duration study could unlock the secrets to MP use and could make levodopa available in regions of the world without proper access to Parkinson’s medications.

Selected References

Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004;75:1672-77.

Cilia R, Laguna J, Cassani E, Cereda E, Pozzi NG, Isaias IU, Contin M,
Barichella M, Pezzoli G. Mucuna pruriens in Parkinson disease: A double-blind,randomized, controlled, crossover study. Neurology. 2017 Jul 5. pii:10.1212/WNL.0000000000004175. doi: 10.1212/WNL.0000000000004175. [Epub ahead of print] PubMed PMID: 28679598.

Okun MS. Use of Mucuna Pruriens Powder Instead of Levodopa. NEJM Journal Watch Neurology, August 2017.

You can find out more about PF's National Medical Director, Dr. Michael S. Okun, by also visiting the Center of Excellence, University of Florida Health Center for Movement Disorders and Neurorestoration. Dr. Okun is also the author of the Amazon #1 Parkinson's Best Seller 10 Secrets to a Happier Life and 10 Breakthrough Therapies for Parkinson's Disease. You can read more from Dr. Okun in the What's Hot in PD? archives.

Study Pinpoints Cause of Dyskinesias from Cell Transplant Therapy for Parkinson’s
Thursday, June 30, 2016

Researchers have discovered a potential mechanism underlying dyskinesiasAbnormal, involuntary body movements that can appear as jerking, fidgeting, twisting and turning movements; frequently caused by dopaminergic medications to treat Parkinson’s. among some people with Parkinson’s disease (PD) who have been treated with c

New Gene Discovered That Causes Inherited Parkinson’s Disease
Tuesday, June 28, 2016

Scientists have identified a new gene, called TMEM230, that causes Parkinson’s disease (PD) when just one of a person’s two copies of the gene is mutated.

Is Parkinson’s Disease on the Rise?
Monday, June 20, 2016

A new study finds that the number of new cases per year of Parkinson’s disease (PD), and related diseases known as parkinsonisms, may have increased over a 30-year period. A possible explanation lies in the dramatic decline in cigarette smoking in recent decades. The research appears in the June 20 online edition of JAMA Neurology.

Study Questions Physical Therapy for Early and Moderate-Stage Parkinson’s
Wednesday, June 1, 2016

People with early and moderate-stage Parkinson’s disease (PD) with no clear need for physical or occupational therapy who received a “low-dose” program did not see an improvement in their ability to carry out daily activities, according to research published on January 19 in the online edition of JAMA Neurology. The authors conclude that more structured and intensive physical and occupational therapy should be tested for all

Inhaled Levodopa Provides Relief for “Off” Periods
Friday, May 20, 2016

According to a new study, an experimental inhaled form of levodopaThe medication most commonly given to control the movement symptoms of Parkinson’s, usually with carbidopa.

FDA Approves Nuplazid™ for Treatment of Psychosis in Parkinson’s
Tuesday, May 3, 2016

The Parkinson’s Disease Foundation (PDF) alerts the community that pimavanserin (Nuplazid™) has been approved by the US Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The drug’s manufacturer, Acadia Pharmaceuticals Inc., announced the approval on April 29.

Stem Cell Therapies for Parkinson’s: Five Questions to Ask Before Participating in a Clinical Trial
Tuesday, April 26, 2016

How can people with Parkinson’s disease (PD) assess the safety of clinical trials Research studies in humans that aim to test a new intervention – this could be a drug, surgery or therapy like exercise or diet guidelines – to make sure it is effective and safe. for stem cell therapies?

Progress Toward Understanding Fatigue in Parkinson’s Disease
Thursday, March 24, 2016

The results of the Parkinson’s Disease Foundation’s (PDF) Conference on Fatigue, the first meeting supported by our Community Choice Research Awards, have now been published in the online editions of npj Parkinson’s Disease on January 14 and Movement Disorders on February 16.

Rosacea May Signal Increased Parkinson’s Risk
Monday, March 21, 2016

A new study finds that people with rosacea — persistently red, and sometimes bumpy, skin on the face — have nearly twice the risk of developing Parkinson’s disease (PD) compared to the general population. The study appears in the March 21 online edition of JAMA Neurology.

Early Weight Loss May Signal Faster Parkinson’s Progression
Friday, March 18, 2016

People with Parkinson’s disease (PD) who lost weight early on in the disease tended to experience a faster progression of motor symptoms over time compared to those whose weight held steady or who gained weight, according to the results of a study published in the January 11 online edition of JAMA Neurology.

Pages

mail icon

Subscribe here to get the latest news on treatments, research and other updates.